Healthcare and life sciences are entering a period in which therapeutic innovation and medical technology are becoming increasingly interconnected. Medicines are no longer always developed, delivered or evaluated as independent products. They are increasingly supported by diagnostics, medical devices, digital monitoring, data platforms and clinical decision tools that help identify appropriate patients, improve treatment delivery and measure outcomes. This convergence is creating a more integrated healthcare model in which scientific discovery, technology and clinical practice operate as parts of a connected system.
The development of precision healthcare is central to this change. Traditional treatment models often apply similar interventions across broad patient populations, even though individuals may respond differently because of their genetics, biology, disease progression or lifestyle. Precision healthcare uses biological, genetic and clinical information to divide patients into more clearly defined groups and select treatments that are more likely to benefit them. The therapeutic component may be a biologic drug, cell therapy, RNA-based medicine or targeted treatment, while the supporting technology may include genetic testing, medical imaging, a drug-delivery device or a digital monitoring platform.
The continued development of novel medicines demonstrates the strength of the therapeutic innovation pipeline. In 2025, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research approved 46 drugs that had not previously been approved or marketed in the United States. These approvals were in addition to decisions that expanded existing medicines into new indications and patient populations. The number and range of approvals show that innovation continues across different diseases, technologies and treatment approaches, providing a foundation for further development in diagnostics, devices and patient-management systems.
Medical technology is evolving alongside therapeutic science. Modern medtech extends beyond conventional equipment and includes robotic surgery, minimally invasive devices, connected monitoring, intelligent imaging, diagnostic platforms and digitally supported treatment delivery. For 2026, life-sciences executives identified AI-enabled diagnostics as a leading medtech development priority, while health-information technology and AI-supported workflow solutions were widely viewed as potential sources of near-term revenue. These developments indicate that medtech is becoming increasingly important not only in diagnosing disease but also in selecting treatments, supporting clinical decisions and monitoring patient progress.
This convergence is already visible across major areas of healthcare. In oncology, companion diagnostics can help determine whether a patient is likely to respond to a targeted medicine. In cardiovascular care, implantable and wearable devices can generate information that supports earlier intervention and continued treatment management. In diabetes, medicines, glucose-monitoring systems and automated delivery devices are increasingly combined within a single care pathway. Similar models are emerging in neurology, rare diseases and immunology, where advanced diagnostics and monitoring can improve patient selection and provide evidence of how treatments perform outside controlled clinical trials.
Artificial intelligence is likely to reinforce these connections, although its long-term value will depend on practical application rather than the use of AI as a broad marketing label. Within therapeutics, AI can help analyse biological data, identify drug targets, select potential molecules and improve clinical-trial design. Within medtech, it can support medical imaging, diagnostic interpretation, patient monitoring and healthcare workflows. Deloitte’s 2026 life-sciences outlook found that investment in AI-enabled platforms was considered a significant growth driver by both biopharma and medtech executives, with particularly strong interest among medtech leaders.
The United States remains central to the development and commercialisation of integrated healthcare innovation. However, life-sciences innovation is becoming increasingly global. Scientific research may originate in one country, clinical trials may operate across several regions, manufacturing may be located in specialised international centres and commercial partnerships may provide access to multiple healthcare markets. Europe offers significant capabilities in medical research, pharmaceutical development and medical-device manufacturing. Asian markets are contributing growing scientific expertise, large patient populations and specialised production capacity. The most scalable healthcare companies may therefore combine international research and development with a strong U.S. regulatory and commercial strategy.
Women’s health provides an important example of how therapeutics and medtech can create more precise and connected models of care. Conditions associated with reproductive health, menopause, maternal care, endometriosis, ovarian health and diseases that affect women differently have historically received a relatively small share of healthcare investment. Women and girls represent close to half of the global population, yet women’s health received only 6% of private healthcare investment measured in the World Economic Forum’s 2026 outlook. Capital has also historically been concentrated in reproductive and maternal health, leaving broader areas of women’s health less developed.
Scientific and technological progress is now supporting a wider view of the sector. Cell biology, hormonal science, genetic testing, diagnostics, remote monitoring and targeted treatments can address women’s health across different life stages rather than only during pregnancy or fertility treatment. The category can include therapeutics for menopause and gynaecological conditions, diagnostic tools for earlier disease detection, devices supporting reproductive and maternal care, and data platforms designed to recognise sex-specific differences in symptoms and treatment responses. Addressing women’s health outcomes could also produce broader social and economic benefits; estimates cited by the World Economic Forum suggest that narrowing the women’s health gap could contribute at least $1 trillion annually to the global economy by 2040.
For investors, the convergence of therapeutics and medtech creates a need for a more comprehensive evaluation framework. Scientific quality remains essential, but it must be assessed alongside clinical evidence, intellectual-property protection, regulatory strategy, manufacturing capability, reimbursement and integration into medical practice. A strong product must not only demonstrate that it works; it must also fit into a practical care pathway and produce outcomes that matter to patients, clinicians and healthcare payers. Businesses that successfully connect these elements may establish stronger and more durable market positions than companies relying on a single technological feature.
Family offices and other long-term investors can participate through specialist life-sciences funds, co-investments, selected direct holdings and companies providing enabling capabilities such as diagnostics, clinical research, manufacturing and treatment-delivery infrastructure. Family offices allocated an average of 42% of their portfolios to alternative assets in 2025, including 21% to private equity, indicating that private-market exposure remains a significant part of their investment strategies. Their flexible investment horizons may be well suited to healthcare businesses that require time to complete clinical development, obtain regulatory approval and build commercial adoption. Nevertheless, patient capital should be combined with specialist scientific due diligence, disciplined valuations and diversification across technologies and development stages. A balanced allocation across therapeutics, medtech, women’s health and enabling infrastructure can provide investors with exposure to the continued evolution of precision healthcare while reducing dependence on the outcome of any single clinical programme.
Aceana Group, Insights
